REVIUM Rx. RVRC

Annual Quarterly

No quarterly revenue total was found in REVIUM Rx.'s SEC filings.

REVIUM Rx. (RVRC) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $842,000 in cash and investments and $128,000 in total debt.

Revenue
—
Net income
$-748,000
-3.2% vs prior quarter
Operating cash flow
$-626,000
-15.7% vs prior quarter
Free cash flow
—
EPS
$0.01
+0.0% vs prior quarter
Dividend per share
None
Shares outstanding
60.73M
+0.0% vs prior quarter
Net cash
$714,000
Q2 FY2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RVRC (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company, Emerging growth company
SEC CIK
1839140

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Operating income
-$732,000
-$739,000
Net income
-$748,000
-$725,000
Diluted EPS
$0.01
$0.01
Operating cash flow
-$626,000
-$541,000
Total assets
$7.1M
$7.8M
Total liabilities
$1.6M
$1.6M
Stockholders' equity
$5.5M
$6.2M
Cash and investments
$842,000
$920,000
Total debt
$128,000
$151,000

Recent SEC filings

Form Description Filed Period
10-Q Quarterly report Aug 13, 2026 Jun 30, 2026
8-K Current report
Officer or director change
 Jun 22, 2026 Jun 16, 2026
8-K Current report
Officer or director change
 Jun 1, 2026 May 27, 2026
10-Q Quarterly report May 14, 2026 Mar 31, 2026
8-K Current report
Officer or director change
 Apr 20, 2026 Apr 14, 2026
10-K Annual report Mar 31, 2026 Dec 31, 2025

All 13 REVIUM Rx. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.